SE9301831D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SE9301831D0
SE9301831D0 SE19939301831A SE9301831A SE9301831D0 SE 9301831 D0 SE9301831 D0 SE 9301831D0 SE 19939301831 A SE19939301831 A SE 19939301831A SE 9301831 A SE9301831 A SE 9301831A SE 9301831 D0 SE9301831 D0 SE 9301831D0
Authority
SE
Sweden
Prior art keywords
pct
date
pharmaceutical compositions
sec
pub
Prior art date
Application number
SE19939301831A
Other languages
English (en)
Inventor
*Leander Kurt
*Rosen Boerje
Original Assignee
Analytecon S A
Conpharm Ab Med Avd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Analytecon S A, Conpharm Ab Med Avd filed Critical Analytecon S A
Priority to SE19939301831A priority Critical patent/SE9301831D0/sv
Publication of SE9301831D0 publication Critical patent/SE9301831D0/sv
Priority to US08/553,423 priority patent/US5637571A/en
Priority to SK1464-95A priority patent/SK280005B6/sk
Priority to PCT/SE1994/000493 priority patent/WO1994027614A1/en
Priority to CA002163887A priority patent/CA2163887A1/en
Priority to HU9503351A priority patent/HUT73812A/hu
Priority to EP94917855A priority patent/EP0700296A1/en
Priority to UA95125474A priority patent/UA41367C2/uk
Priority to AU69398/94A priority patent/AU694431B2/en
Priority to CN94192741A priority patent/CN1126947A/zh
Priority to JP7500542A priority patent/JPH09505270A/ja
Priority to RU95122727A priority patent/RU2148407C1/ru
Priority to CZ953106A priority patent/CZ285590B6/cs
Priority to BR9406655A priority patent/BR9406655A/pt
Priority to NO954806A priority patent/NO308883B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SE19939301831A 1993-05-28 1993-05-28 Pharmaceutical compositions SE9301831D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE19939301831A SE9301831D0 (sv) 1993-05-28 1993-05-28 Pharmaceutical compositions
BR9406655A BR9406655A (pt) 1993-05-28 1994-05-25 Uso de pelo menos um acetal de podofilotoxina-béta-D-glucopiranosideo ou de 4'-demetilpodofilotoxina-béta-D-glucopiranosídeo e processo de tratamento de um hospedeiro afilgido com um estado de amiloidose
EP94917855A EP0700296A1 (en) 1993-05-28 1994-05-25 Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
AU69398/94A AU694431B2 (en) 1993-05-28 1994-05-25 Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
PCT/SE1994/000493 WO1994027614A1 (en) 1993-05-28 1994-05-25 Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
CA002163887A CA2163887A1 (en) 1993-05-28 1994-05-25 Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
HU9503351A HUT73812A (en) 1993-05-28 1994-05-25 Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
US08/553,423 US5637571A (en) 1993-05-28 1994-05-25 Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
UA95125474A UA41367C2 (uk) 1993-05-28 1994-05-25 Застосування лігнін-похідних для одержання фармацевтичної композиції для лікування станів вторинного амілоїдозу та спосіб лікування з її використанням
SK1464-95A SK280005B6 (sk) 1993-05-28 1994-05-25 Použitie lignanových derivátov
CN94192741A CN1126947A (zh) 1993-05-28 1994-05-25 木脂素衍生物在制备治疗淀粉样变性状态的药物组合物中的应用
JP7500542A JPH09505270A (ja) 1993-05-28 1994-05-25 類澱粉症状態を治療する医薬組成物調製のためのリグナン誘導体の使用
RU95122727A RU2148407C1 (ru) 1993-05-28 1994-05-25 Применение лигнановых производных для получения фармацевтических композиций для лечения состояний амилоидоза
CZ953106A CZ285590B6 (cs) 1993-05-28 1994-05-25 Použití nejméně jednoho acetalu podophyllotoxin-ß-D-glukopyranosidu nebo 4´-demethylpodophyllotoxin-ß-D-glukopyranosidu k přípravě farmaceutických kompozic pro léčení či profylaxi stavů amyloidosy
NO954806A NO308883B1 (no) 1993-05-28 1995-11-27 Anvendelse av lignanderivater ved fremstilling av farmasøytiske preparater for behandling av amyloidosetilstander

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301831A SE9301831D0 (sv) 1993-05-28 1993-05-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SE9301831D0 true SE9301831D0 (sv) 1993-05-28

Family

ID=20390089

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939301831A SE9301831D0 (sv) 1993-05-28 1993-05-28 Pharmaceutical compositions

Country Status (15)

Country Link
US (1) US5637571A (sv)
EP (1) EP0700296A1 (sv)
JP (1) JPH09505270A (sv)
CN (1) CN1126947A (sv)
AU (1) AU694431B2 (sv)
BR (1) BR9406655A (sv)
CA (1) CA2163887A1 (sv)
CZ (1) CZ285590B6 (sv)
HU (1) HUT73812A (sv)
NO (1) NO308883B1 (sv)
RU (1) RU2148407C1 (sv)
SE (1) SE9301831D0 (sv)
SK (1) SK280005B6 (sv)
UA (1) UA41367C2 (sv)
WO (1) WO1994027614A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4677496A (en) * 1995-02-21 1996-09-11 Takeda Chemical Industries Ltd. Use of helioxanthin as an enhancer of cell differentiation inducing factors
AU1529297A (en) * 1996-01-24 1997-08-20 Warner-Lambert Company Method of imaging amyloid deposits
KR100416120B1 (ko) * 1997-11-15 2004-05-07 동화약품공업주식회사 천연물로부터 분리한 신규 리그난계통의 항종양 물질
CU20130027A7 (es) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB823068A (en) * 1955-05-13 1959-11-04 Sandoz Ltd Condensation products from glucosides
HU201672B (en) * 1984-12-28 1990-12-28 Conpharm Ab Process for producing pharmaceutical compositions comprising podophyllotoxin

Also Published As

Publication number Publication date
CZ285590B6 (cs) 1999-09-15
UA41367C2 (uk) 2001-09-17
CN1126947A (zh) 1996-07-17
NO954806L (no) 1996-01-26
SK146495A3 (en) 1996-06-05
RU2148407C1 (ru) 2000-05-10
SK280005B6 (sk) 1999-07-12
US5637571A (en) 1997-06-10
NO308883B1 (no) 2000-11-13
HUT73812A (en) 1996-09-30
CA2163887A1 (en) 1994-12-08
AU6939894A (en) 1994-12-20
HU9503351D0 (en) 1996-01-29
CZ310695A3 (en) 1996-04-17
EP0700296A1 (en) 1996-03-13
AU694431B2 (en) 1998-07-23
BR9406655A (pt) 1996-03-19
JPH09505270A (ja) 1997-05-27
NO954806D0 (no) 1995-11-27
WO1994027614A1 (en) 1994-12-08

Similar Documents

Publication Publication Date Title
DE69326776T2 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
DE69530081T2 (de) Gastrin- und cck-antagonisten
BR9611175A (pt) Compostos ou suas composições e uso dos mesmo
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
NO983002L (no) Vitronectin-reseptor-antagonister
DK0652773T3 (da) Anvendelse af nor- og homo-galdesyrederivater somabsorptionsfremmende bestanddele i lægemidler
DE69326250D1 (de) Neuropeptide y antagoniste
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DE69811062T2 (de) Polyaromatische antivirale zusammensetzungen
SE9304098L (sv) Anordning för fallskyddad klättring
FI972434A0 (sv) Farmaceutisk komposition innehållande lamotrigin
AU1081695A (en) The use of an ester of inositoltrisphosphate for the preparing of medicaments
SE9301831D0 (sv) Pharmaceutical compositions
DK0787135T3 (da) Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh
ITPD920145A1 (it) Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
DK0586589T3 (da) Amylin- eller amylinanalogpræparat, som eventuelt indeholder insulin, til behandling af anoreksi og beslægtede tilstande
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida
NO952885D0 (no) Diarylalkylpiperidiner som er anvendbare som multi-legemiddelresistente tumormidler
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
DE69430074T2 (de) Analgetische 4-arylisoindolen
SE9401596D0 (sv) New compounds
GR1002385B (el) Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.
DK0678022T3 (da) Anvendelse af riluzol ved fremstilling af lægemidler, som er anvendelige til behandling af stråleskader
FI952855A0 (sv) Nya trizolokinazoliner, framställning och användning av dem